GlassScriptPhysician profile
Angela C Bucci
NPI 1730167289
$5,168.96
in general payments reported to CMS, 2019-2025
32 companies · $71.11 in 2025
The $71.11 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,471 · 2020: $739 · 2021: $145 · 2022: $816 · 2023: $1,633 · 2024: $294 · 2025: $71.11.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,975 · Education: $23.89.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,974.76 |
| Education | $23.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mannkind Corporation | $1,221.34 | 2019-2023 | Afrezza |
| Novo Nordisk INC | $676.83 | 2019-2024 | Ozempic, Rybelsus, Sogroya |
| Lilly USA, LLC | $478.28 | 2019-2024 | Jardiance, Mounjaro, Zepbound |
| Abbott Laboratories | $450.94 | 2019-2024 | Freestyle Libre 3 |
| Dexcom, INC. | $406.46 | 2019-2024 | Dexcom G6 Transmitter |
| Bayer Healthcare Pharmaceuticals INC. | $249.62 | 2022-2025 | |
| Echosens North America, INC. | $172.44 | 2023 | Fibroscan |
| Esperion Therapeutics, INC. | $149.44 | 2022-2023 | Nexletol |
| Boehringer Ingelheim Pharmaceuticals, INC. | $148.81 | 2019-2022 | |
| Aegerion Pharmaceuticals, INC. | $144.20 | 2019 | |
| Amgen INC. | $119.66 | 2019-2024 | Tepezza |
| Abbvie INC. | $109.37 | 2020-2024 | |
| Amarin Pharma, INC. | $109.00 | 2019-2020 | |
| Corcept Therapeutics | $106.94 | 2019-2024 | Korlym |
| Tandem Diabetes Care, INC. | $96.16 | 2019-2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insulet Corporation | $69.26 | 2019-2023 | Omnipod |
| Astrazeneca Pharmaceuticals LP | $66.59 | 2019-2023 | Farxiga |
| Sanofi-Aventis U.S. LLC | $46.75 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $46.69 | 2019-2023 | Cycloset |
| Nevro Corp. | $42.31 | 2022-2023 | Senza |
| Radius Health, INC. | $40.81 | 2019-2023 | Tymlos |
| Novartis Pharmaceuticals Corporation | $33.65 | 2023-2024 | |
| Pfizer INC. | $30.23 | 2019 | |
| Antares Pharma, INC. | $23.20 | 2024 | Xyosted |
| Janssen Pharmaceuticals, INC | $20.11 | 2019 | |
| Ibsa Pharma INC. | $19.64 | 2023 | Tirosint, Licart |
| Shire North American Group INC | $19.53 | 2019 | |
| Medtronic Minimed, INC. | $17.28 | 2019 | |
| Amryt Pharma Holdings LTD | $17.17 | 2023 | Mycapssa |
| Boston Scientific Corporation | $12.46 | 2019 | |
| Merck Sharp & Dohme LLC | $12.18 | 2019 | |
| Valeritas, INC. | $11.61 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Angela Bucci listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.